

Appln. No. 09/125,841
After Final Amendment dated June 25, 2004
Reply to Final Office Action of February 27, 2004

Amendments to the Claims

The listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claims 1-28. (Cancelled)

29. (Currently Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion.
30. (Currently Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) and anti-CD3 monoclonal antibody.
31. (Currently Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) at about 600 IU/ml and anti-CD3 monoclonal antibody at between about 1 and 100 ng/ml.
32. (Currently Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) at about 600 IU/ml and anti-CD3 monoclonal antibody at between about 1 and 100 ng/ml, and wherein the amount of IL-2 is lowered to about 120 IU/ml after 7 days of expansion.
33. (Currently Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) at about 600

Appln. No. 09/125,841
After Final Amendment dated June 25, 2004
Reply to Final Office Action of February 27, 2004

IU/ml and anti-CD3 monoclonal antibody at between about 1 and 100 ng/ml, wherein the amount of IL-2 is lowered to about 120 IU/ml after 7 days of expansion, and wherein said expansion extends to at least about 10 days.

34. (Currently Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free macrophage media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) at about 600 IU/ml and anti-CD3 monoclonal antibody at between about 1 and 100 ng/ml.
35. (Currently Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free macrophage media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) and anti-CD3 monoclonal antibody.

Claims 36-41. (Cancelled)